利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.023 秒)

    VEGF traps and therapeutic uses thereof
    1.
    发明申请
    VEGF traps and therapeutic uses thereof 有权
    VEGF陷阱及其治疗用途

    公开(公告)号：US20040014667A1

    公开(公告)日：2004-01-22

    申请号：US10609775

    申请日：2003-06-30

    发明人： Thomas J. Daly ,  James P. Fandl ,  Nicholas J. Papadopoulos

    IPC分类号： A61K038/17 ,  C07K014/71 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K2319/00

    摘要： Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF mini-traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.

    摘要翻译： 能够结合血管内皮生长因子（VEGF）的核酸分子和多聚体蛋白质。 公开了VEGF微型陷阱，其可用于治疗VEGF相关病症和疾病，并且被特别设计用于特定器官，组织和/或细胞的局部给药。

    Isolated FGF receptor
    2.
    发明申请
    Isolated FGF receptor 失效
    分离的FGF受体

    公开(公告)号：US20020090651A1

    公开(公告)日：2002-07-11

    申请号：US10016447

    申请日：2001-12-10

    申请人： President and Fellows of Harvard College

    发明人： Marc W. Kirschner ,  Noriyuki Kinoshita

    IPC分类号： G01N033/53 ,  C12Q001/68 ,  C12Q001/48 ,  C07H021/04 ,  C12N001/18 ,  C07K014/71

    CPC分类号： C07K14/46 ,  A61K38/00 ,  C07K14/705 ,  C07K16/18 ,  C12N15/1055 ,  C12N15/81

    摘要： Disclosed herein are compositions and methods which are useful in the identification and isolation of components involved in transmembrane receptor-mediated signaling. Such components include the receptors themselves (e.g., tyrosine kinase receptors, cytokine receptors and tyrosine phosphatase receptors), as well as ligands which bind the receptors and modulators of the downstream intracellular catalytic event which characterizes receptor-mediated signalling. Two novel ligands for the FGF receptor and the nucleotide sequences encoding them are also described.

    摘要翻译： 本文公开了可用于鉴定和分离参与跨膜受体介导的信号传导的成分的组合物和方法。 这些组分包括受体本身（例如酪氨酸激酶受体，细胞因子受体和酪氨酸磷酸酶受体）以及结合受体介导的信号传导的下游细胞内催化事件的受体和调节剂的配体。 还描述了用于FGF受体的两种新型配体和编码它们的核苷酸序列。

    Hematopoietin receptor
    7.
    发明申请
    Hematopoietin receptor 审中-公开
    血细胞生成素受体

    公开(公告)号：US20040152161A1

    公开(公告)日：2004-08-05

    申请号：US10715667

    申请日：2003-11-14

    申请人： Immunex Corporation

    发明人： David J. Cosman ,  Bruce A. Mosley ,  Robert F. DuBose ,  Steven R. Wiley

    IPC分类号： C07K014/71 ,  C07H021/04

    CPC分类号： G01N33/6863 ,  C07K14/715 ,  C07K2319/00 ,  G01N33/74

    摘要： This invention relates to human and murine HPR1 and human and murine HPR2 polypeptides, new members of the hematopoietin receptor polypeptide family; to methods of making such HPR1 and HPR2 polypeptides; to non-human mammals in which the endogenous genomic sequences encoding HPR1 and/or HPR2 polypeptides have been partially or completely inactivated; to methods of using HPR1 or HPR2 polypeptides to identify compounds that alter HPR1 or HPR2 polypeptide activities; and to methods of preparing medicaments for and/or treating conditions associated with hematopoietin receptor function.

    摘要翻译： 本发明涉及人和鼠HPR1和人和鼠HPR2多肽，造血细胞因子受体多肽家族的新成员; 涉及制备此类HPR1和HPR2多肽的方法; 涉及编码HPR1和/或HPR2多肽的内源基因组序列部分或完全失活的非人哺乳动物; 涉及使用HPR1或HPR2多肽鉴定改变HPR1或HPR2多肽活性的化合物的方法; 以及制备用于和/或治疗与造血细胞受体功能相关的药物的方法。

    Methods for diagnosis of cancer using erbB-3
    8.
    发明申请
    Methods for diagnosis of cancer using erbB-3 审中-公开

    公开(公告)号：US20040063140A1

    公开(公告)日：2004-04-01

    申请号：US10693030

    申请日：2003-10-24

    发明人： Matthias H. Kraus ,  Stuart A. Aaronson

    IPC分类号： C12Q001/68 ,  C07H021/04 ,  C07K014/71 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K16/32 ,  A61K38/00 ,  A61K47/6843 ,  C07K14/82 ,  C07K2317/34 ,  G01N33/5748 ,  G01N33/57484 ,  G01N2500/02 ,  G01N2500/04

    摘要： A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNk Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64% and 67% to a contiguous region within the tyrosine kinase domains of the EGFR and erbB-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12q11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies. Using erbB-3 specific antibodies (polyclonal or monoclonal), the erbB-3 protein was identified as a 180 kDa glycoprotein, gp180erbB-3. The intrinsic catalytic function of gp180erbB-3 was uncovered by its ability to autophosphorylate in vitro. Ligand-dependent signaling of its cytoplasmic domain was established employing transfectants which express a chimeric EGFR/erbB-3 protein, gp180EGFR/erbB-3. EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These findings, combined with the detection of constitutive tyrosine phosphorylation of gp180erbB-3 in 4 out of 12 human mammary tumor cell lines, implicate the activated erbB-3 product in the pathogenesis of some human malignancies. Thus, this invention also relates to a method for detecting a receptor ligand capable of either activating or down-regulating the receptor protein, as well as procedures for purifying the resultant ligand; a method of screening potential ligand analogs for their ability to activate the receptor protein; and procedures for targeting a therapeutic drug to cells having a high level of the receptor protein.

    Multimeric ligands with enhanced stability
    9.
    发明申请
    Multimeric ligands with enhanced stability 有权
    具有增强稳定性的多聚体配体

    公开(公告)号：US20040033948A1

    公开(公告)日：2004-02-19

    申请号：US10419976

    申请日：2003-04-22

    申请人： Greenville Hospital System

    发明人： Wen Yuan Chen

    IPC分类号： A61K038/17 ,  C07K014/71

    CPC分类号： C07K14/61 ,  C07K14/57554 ,  C07K2319/00

    摘要： The present invention provides compositions and methods for making multimeric proteins to increase stability over their monomer. For example, more stable growth hormone and prolactin receptor agonists are provided.

    摘要翻译： 本发明提供了制备多聚体蛋白质以增加其单体稳定性的组合物和方法。 例如，提供更稳定的生长激素和催乳素受体激动剂。

    Cyr61 compositions and methods
    10.
    发明申请
    Cyr61 compositions and methods 失效
    Cyr61组合物和方法

    公开(公告)号：US20040002124A1

    公开(公告)日：2004-01-01

    申请号：US10182432

    申请日：2002-10-16

    发明人： Lester F Lau ,  Cho-Yau Yeung ,  Jeffrey A Greenspan

    IPC分类号： G01N033/574 ,  C07H021/04 ,  A61K039/00 ,  C07K014/71 ,  C12P021/02 ,  C12N005/06

    CPC分类号： C07K14/475 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0368 ,  C12N15/8509 ,  C12N2830/008 ,  G01N33/5008 ,  G01N33/5011 ,  G01N33/5029 ,  G01N33/5055 ,  G01N33/5061 ,  G01N33/5064 ,  G01N33/5067 ,  G01N33/5088 ,  G01N2333/7055

    摘要： Polynucleotides encoding mammalian ECM signaling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signaling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signaling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signaling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signaling molecules. Further provided are methods for using mammalian ECM signaling molecules to screen for, and/or modulate, conditions and disorders associated with angiogenesis, chondrogensis, and oncogenesis; ex vivo methods for using mammalian ECM signaling molecules to prepare blood products are also provided. Additionally, modulators, such as peptide modulators, of an ECM signaling molecule activity are provided. Further provided are methods for screening for modulators of a Cyr61 polypeptide-integrin receptor inteaction, as well as methods of treating conditions and disorders associated with such an interaction.

    摘要翻译： 提供了编码哺乳动物ECM信号分子的多核苷酸，其影响表征诸如血管生成，软骨形成和肿瘤形成等复杂生物学过程的细胞粘附，迁移和增殖活性。 多核苷酸组合物包括包含ECM信号分子编码序列或生物等同物的部分或全部的DNA和RNA。 还提供了多肽组合物。 多肽组合物包含哺乳动物ECM信号分子，肽片段，能够与ECM信号分子的受体相互作用的抑制肽，以及识别Cyr61的抗体产物。 还提供了用于产生哺乳动物ECM信号分子的方法。 还提供了使用哺乳动物ECM信号分子来筛选和/或调节与血管生成，软骨融合和肿瘤发生相关的病症和病症的方法。 还提供了使用哺乳动物ECM信号分子来制备血液制品的离体方法。 另外，提供了ECM信号分子活性的调节剂，例如肽调节剂。 进一步提供了用于筛选Cyr61多肽整合素受体整合的调节剂的方法，以及治疗与这种相互作用相关的病症和障碍的方法。